Mekinist

Summary

Name(s) Target Manufacturer Status
Mekinist, trametinib MAP2K1, MAP2K2 GlaxoSmithKline FDA approved for: Melanoma, BRAF V600E Mutated, Melanoma, BRAF V600K Mutated

Clinical Trials

Trial Drug Status Phase
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. [NCT01682083] Mekinist, Tafinlar Recruiting Phase 3
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma [NCT02224781] Mekinist, Tafinlar, Yervoy, nivolumab Not yet recruiting Phase 3
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery [NCT02199730] Mekinist, Tafinlar Recruiting Phase 2
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain [NCT02039947] Mekinist, Tafinlar Recruiting Phase 2
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [NCT01726738] Mekinist, Tafinlar Recruiting Phase 2
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery [NCT02196181] Mekinist, Tafinlar Recruiting Phase 2
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor [NCT01619774] Mekinist, Tafinlar Recruiting Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma [NCT01979523] GSK2141795, Mekinist Recruiting Phase 2
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery [NCT01701037] Mekinist, Tafinlar Recruiting Phase 2
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites [NCT01978236] Mekinist, Tafinlar Recruiting Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma [NCT01941927] GSK2141795, Mekinist Recruiting Phase 2
GSK1120212 Rollover Study [NCT01376310] Abraxane, Afinitor, Alimta, Carboplatin, Gemzar, Mekinist, Tarceva, Taxotere Recruiting Phase 2
NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors [NCT01827384] Afinitor, Carboplatin, MK-1775, Mekinist, Temodar, veliparib Recruiting Phase 2
Combi-Neo Study for Stage IV Melanoma [NCT02231775] Mekinist, Tafinlar Not yet recruiting Phase 2
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone [NCT02027961] MEDI4736, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma [NCT02110355] AMG 232, Mekinist, Tafinlar Not yet recruiting Phase 1/Phase 2
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients [NCT02143050] Mekinist, Metformin, Tafinlar Recruiting Phase 1/Phase 2
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery [NCT01970956] ABT-263, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery [NCT01989585] ABT-263, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022) [NCT02130466] Keytruda, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma [NCT01767454] Mekinist, Tafinlar, Yervoy Recruiting Phase 1
A Study of LY2875358 in Participants With Advanced Cancer [NCT01287546] LY2875358, Mekinist, Tarceva Recruiting Phase 1
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors [NCT01231594] Mekinist, Tafinlar Recruiting Phase 1
Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery [NCT01940809] Mekinist, Tafinlar, Yervoy Recruiting Phase 1
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors [NCT02065063] Mekinist, PD-0332991 Recruiting Phase 1
Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery [NCT02097225] AT13387, Mekinist, Tafinlar Recruiting Phase 1
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma [NCT02138292] Mekinist, digoxin Recruiting Phase 1
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [NCT01725100] Mekinist Recruiting Phase 1
Trametinib in Treating Patients With Advanced Cancer and Hepatic Dysfunction [NCT02070549] Mekinist Recruiting Phase 1
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases [NCT02015117] Mekinist Recruiting Phase 1
#